08/15/2026
Belite Weight Management Research Brief – Week 2 1. Orforglipron after Wegovy or Zepbound. ATTAIN-MAINTAIN found that patients transitioned from tirzepatide or semaglutide to oral orforglipron (Foundayo) maintained substantially more of their prior weight reduction than patients switched to placebo. A new option in the maintenance discussion. https://vist.ly/5evhr 2. CagriSema vs. Zepbound. CagriSema delivered 23% average weight loss in its head-to-head trial —
right-arrow
Read More "Belite Weight Management Research Brief – Week 2"right-arrow
The post Belite Weight Management Research Brief – Week 2 appeared first on BeLite Medical Center. https://vist.ly/5evht
Explore the latest GLP-1 weight-loss advances, including oral orforglipron after Wegovy or Zepbound, CagriSema vs. Zepbound, maintenance strategies, and muscle-preserving nutrition.